Biology Reference
In-Depth Information
Choi YH, Park S, Hockman S, Zmuda-Trzebiatowska E, Svennelid F, Haluzik M, Gavrilova O,
Ahmad F, Pepin L, Napolitano M, Taira M, Sundler F, Stenson HL, Degerman E,
Manganiello VC (2006) Alterations in regulation of energy homeostasis in cyclic nucleotide
phosphodiesterase 3B-null mice. J Clin Invest 116:3240-3251
Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases:
essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
Creager MA, Pande RL, Hiatt WR (2008) A randomized trial of iloprost in patients with
intermittent claudication. Vasc Med 13:5-13
Dal LA, De MD, Flore R, Gaetani E, Gasbarrini A, Gerardino L, Pola R, Santoliquido A,
Serricchio M, Tondi P, Nolfe G (1999) Effects of propionyl-L-carnitine on peripheral arterial
obliterative disease of the lower limbs: a double-blind clinical trial. Drugs Exp Clin Res
25:29-36
Dawson DL, Cutler BS, Meissner MH, Strandness DEJ (1998) Cilostazol has beneficial effects in
treatment of intermittent claudication: results from a multicenter, randomized, prospective,
double-blind trial. Circulation 98:678-686
Dawson DL, Cutler BS, Hiatt WR, Hobson RW, Martin JD, Bortey EB, Forbes WP, Strandness DE
(2000) A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
Am J Med 109:523-530
Dawson DL, Zheng Q, Worthy SA, Charles B, Bradley DV Jr (2002) Failure of pentoxifylline or
cilostazol to improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in
claudication. Angiology 53:509-520
de la Cruz JP, Romero MM, Sanchez P, de la Sanchez CF (1993) Antiplatelet effect of pentoxifyl-
line in human whole blood. Gen Pharmacol 24:605-609
Dimmeler S, Haendeler J, Galle J, Zeiher AM (1997) Oxidized low-density lipoprotein induces
apoptosis of human endothelial cells by activation of CPP32-like proteases: a mechanistic clue
to the 'response to injury' hypothesis. Circulation 95:1760-1763
Douglas JS Jr, Holmes DR Jr, Kereiakes DJ, Grines CL, Block E, Ghazzal ZM, Morris DC,
Liberman H, Parker K, Jurkovitz C, Murrah N, Foster J, Hyde P, Mancini GB, Weintraub WS
(2005) Coronary stent restenosis in patients treated with cilostazol. Circulation 112:2826-2832
Dunkel B, Rickards KJ, Page CP, Cunningham FM (2007) Phosphodiesterase isoenzymes in
equine platelets and their influence on platelet adhesion. Am J Vet Res 68:1354-1360
Dunkern TR, Hatzelmann A (2005) The effect of Sildenafil on human platelet secretory function is
controlled by a complex interplay between phosphodiesterases 2, 3 and 5. Cell Signal
17:331-339
Ehrly AM (1978) The effect of pentoxifylline on the flow properties of human blood. Curr Med
Res Opin 5:608-613
ElamMB, Heckman J, Crouse JR, Hunninghake DB, Herd JA, Davidson M, Gordon IL, Bortey EB,
Forbes WP (1998) Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in
patients with intermittent claudication. Arterioscler Thromb Vasc Biol 18:1942-1947
Ferraresi I, Bozzini F, Torta D, Frigerio R, Bernasconi C, Agostoni A (1983) In vitro effects of
pentoxifylline on hemoglobin affinity for oxygen and electrolytic equilibrium of human blood.
Ric Clin Lab 13:459-465
Fischmeister R, Castro LR, bi-Gerges A, Rochais F, Jurevicius J, Leroy J, Vandecasteele G (2006)
Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide
phosphodiesterases. Circ Res 99:816-828
Fong M, Yoshitake M, Kambayashi J, Liu Y (2010) Cilostazol increases tissue blood flow in
contracting rabbit gastrocnemius muscle. Circ J 74:181-187
Frantz S (2005) Drug discovery: playing dirty. Nature 437:942-943
Fukasawa M, Nishida H, Sato T, Miyazaki M, Nakaya H (2008) 6-[4-(1-Cyclohexyl-1H-
tetrazol-5-yl)butoxy]-3, 4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase
type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+
channels in rabbit hearts. J Pharmacol Exp Ther 326:100-104
